doing more with outcomes: lessons from the parkinson’s ... · from the parkinson’s outcomes...

36
1 Doing More With Outcomes: Lessons from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D.

Upload: others

Post on 14-Jun-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

1

Doing More With Outcomes: Lessons from the Parkinson’s Outcomes ProjectPeter Schmidt, Ph.D.

Page 2: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Science from Art

“Once a treatment enters the mainstream, science is left behind. The next questions —when to use it and on which patients —become matters of judgment, not measurement.”

Page 3: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Feynman Said It First…

3

“Incidentally, psychoanalysis is not a science; it is at best a medical process, and perhaps more like witch-doctoring….”

Page 4: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

However…

4

“If you are sick, I would advise that you go to the witch doctor because he is the man in the tribe who knows the most about the disease; on the other hand, his knowledge is not science.”Richard FeynmanNobel Prize, Physics, 1965

Page 5: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Success Here Isn’t Enough

5

Page 6: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Developing Improvement Science

• Cystic fibrosis

6

USA Matthews Clinic1964 CF median survival: 3 years 21 years1966: 10 years1972: 18 years 95% survival past 18

Page 7: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Witch Doctors?

7

Improved risk with neurologist care

Risk

redu

ctio

n

Page 8: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

How Do We Reach Everyone?

8

Page 9: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

The Parkinson’s Outcomes Project

9

• 7+ years• 14,000+ participants• 20,000+ evaluations• 20+ interventions• 6 outcomes

• Goal: To find and understand the very best care so that we can teach others to provide it.

Page 10: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Age at Onset and Diagnosis

10

692 YOPD

Years30 40 50 60 70 80 90

Page 11: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

713 newly diagnosed Disease duration

427 with 20+ years of PD

0 5 10 15 20 25 30 35

Years

Across the Spectrum

11

Num

ber o

f Ind

ivid

uals

Page 12: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

NPF’s Parkinson’s Outcomes Project

Demographics

Social

Clinical evaluation

Interventions

Patient-reported outcomes

Page 13: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Very Simple Tests…

13

Page 14: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

… But High Resolution

14

Page 15: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Insight from Segments

15

You can’t “adjust” this away.

Page 16: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Approach to Measurement• Clinical Value Compass (Nelson, et al., 1996)

16

FunctionalC

linic

al

Utilization

Satisfaction

Patient reported

Clinically measured

Utilization & costs

Setting expectations, achieving goals

Page 17: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

17

Learning to Fight Parkinson’sUnderstanding Outcomes

Page 18: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Are There Outliers?

18

Regression to the mean?

Baseline status(z-score)

2-year delta(z-score)

Overall 6 outcome score

Negative outliers

Page 19: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Are There Outliers?

19

Baseline status(z-score)

2-year delta(z-score)

Overall 6 outcome scoreSubtype?

Page 20: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Comparing Centers• Goals for case-mix comparisons:

– Minimal adjustment: results ~ reality

– Map results to standardized domain so that we can look across outcomes

– Comparisons inform further investigation, they are not answers

20

Page 21: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Case Mix: Sex and Comorbidities• For each outcome, adjust individual results for

sex and comorbidities as categorical variables.

21

PDQ

-39

Comorbidities

Subjects were mapped to male

with 0 comorbidities

Page 22: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

1 2 3 4 51 9.9 8.8 11.2 10.3 12.22 9.2 9.2 11.1 10.6 11.23 9.5 11.4 9.6 13.8 15.04 11.8 13.5 16.1 15.0 17.55 15.7 20.3 13.6 19.3 20.9

Center I

Center Summary Score

22

1 2 3 4 51 4.6% 4.4% 4.5% 3.3% 3.1%2 4.4% 3.5% 3.8% 4.3% 4.0%3 3.8% 4.3% 3.7% 4.1% 4.3%4 3.6% 4.0% 4.1% 3.9% 4.5%5 3.6% 3.8% 4.0% 4.4% 4.2%

Total Cohort

Duration quintiles

Age

qui

ntile

s

Timed up-and-go results

Overall frequency by strataMultiply and Sum

Population weighted average:

13.1seconds

Page 23: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Comparing Centers

23

TUG

scor

e

Distribution of total

population results

Each dot represents one center’s

weighted average

Page 24: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

From Subject Received SizeCategories

Peter RE: Parkin's Disease, Frozen Gait and innovation 2:34

PM 53 KB

From Subject Received SizeCategories

Peter RE: Parkin's Disease, Frozen Gait and innovation 2:34

PM 53 KB

Comparing Centers

24

TUG

scor

e

Page 25: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Comparing Across Outcomes

25

Center Ez-

scor

es; h

ighe

r is b

ette

r

Page 26: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Center G: Leader in Cognition

26

2012 2014 2016

Cogn

itive

sco

rehi

gher

is b

ette

r Center G

Page 27: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Center A: Leader in Falls

27

2012 2014 2016

Cogn

itive

sco

rehi

gher

is b

ette

r

Center A

Page 28: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Looking at All Outcomes

28

Page 29: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Exercise: Changing the Disease Course

Exercise May Put Brakes on QOL Decline in Parkinson’sSAN DIEGO -- Parkinson's patients who exercise regularly have slower declines in quality of life, researchers reported here. In an analysis of data from the National Parkinson Foundation database, patients who reported exercising at least 2.5 hours…

Matched patients who started exercise early (NEE) versus started late (NNE): change in health status.

ΔHR

QL

Higher is worse.

Page 30: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Next Steps

30

Baseline status(z-score)

2-year delta(z-score)

Overall 6 outcome score

Negative outliers

Page 31: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Variance: Mobility

31

Baseline status(z-score)

2-year delta(z-score)

TUG score

Page 32: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Variance: Mobility at Center 5

32

Baseline status(z-score)

TUG score

2D SD metric: 1.9

2-year delta(z-score)

Page 33: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Variance: Mobility at Center 9

33

Baseline status(z-score)

TUG score

2-year delta(z-score)

TUG score

2D SD metric: 0.97

Page 34: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Where Would You Run Your Motor Trial?

34

Center 5Highly predictable longitudinal outcomes

Center 9Highly variable longitudinal outcomes

Page 35: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Precision Care• Improving outcomes while improving science• Alternate/supplement to biomarkers?

35

Accuracy Precision

Page 36: Doing More With Outcomes: Lessons from the Parkinson’s ... · from the Parkinson’s Outcomes Project Peter Schmidt, Ph.D. Science from Art “Once a treatment enters the mainstream,

Thank You

36

“Mathematics is not a science from our point of view…”